What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus

• 2024

  Log in to bookmark this resource.

  Log in
• Haben Debessai; Jefferson Jones; Dana Meaney-Delman; Sonja Rasmussen
PMID: 38061043DOI: https://dx.doi.org/10.1097/AOG.0000000000005492

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This review article discusses two preventive option for the prevention of RSV in infants: a maternal vaccine and a monoclonal antibody for infants. The FDA and CDC recommend the RSVPreF vaccine for pregnant women and nirsevimab for infants at high risk. This article reviews the safety of these two products, current recommendations, and the pros and cons of each option so that obstetricians are informed to counsel pregnant patients on these prevention options.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antibodies, Monoclonal; Antiviral Agents; Infant; Infant, Newborn; Maternal Health; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; United States; Obstetricians

Institutions: Centers for Disease Control and Prevention (CDC); Johns Hopkins University

---

More like this

Who Gets How Much: Funding Formulas in Federal Public Health Programs 2007 · Emory University, Johns Hopkins University Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024 2024 · Centers for Disease Control and Prevention (CDC), Vanderbilt University, Seattle Children's Hospital, Baylor College of Medicine, University of Rochester Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 2024 · Centers for Disease Control and Prevention (CDC), Maximus Federal Services, Inc., ICF

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---